What's the outlook for the CSL share price in April?

Could the ASX biotech giant be on the way back up?

| More on:
A doctor looks unsure.

Image source: Getty images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • One broker predicts the CSL share price could surge as much as 27% 
  • The CSL share price finished in the green on Tuesday
  • The biopharmaceutical company could be one to watch after tonight's federal budget 

The CSL Ltd (ASX: CSL) share price may have suffered since early 2020, but can it recover in the near future?

CSL shares have dropped 21% since 21 February 2020, close to the onset of the COVID-19 pandemic. In today's trade, the company's shares climbed 1.43% to $265.60 apiece.

So what is the outlook for the CSL share price?

Where is the CSL share price heading?

Citi analysts have recently upgraded CSL to a buy with a $335 price target. That's 27% higher than its current value. Citi's price would take the share very close to its five year high of $336.40 on 21 February 2020. The broker is optimistic plasma collection improvements will have a positive impact on the company's shares.

FNArena founder Rudi Filapek-Vandyck also predicts the CSL share price will rise again soon. The analyst believes CSL "will find its mojo again". Filapek-Vandyck added:

I recently bought some extra shares in CSL. The business model was disrupted because of COVID… If I look forward to the next two to three years, I see an environment where CSL will again come to the fore.

Looking to the near future, CSL could also be one of the companies to benefit from onshore manufacturing of pharmaceuticals, announced in the lead up to the federal budget. My Foolish colleague Zach reported today Bloomberg's Jackie Edwards believes this manufacturing push could put CSL in the spotlight. The federal budget will be delivered this evening at 7.30 pm.

JP Morgan analysts have also put an overweight rating on CSL, valuing the company at $295 per share. This is 11% more than the current share price.

CSL recently made the cut for a list of one of the greatest ASX listed companies of all time. QVG Capital included CSL in a list of its ASX "hall of famers".

Share price snapshot

The CSL share price has dropped nearly 9% year to date while it is up a slim 0.08% in the past year.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has gained nearly 10% in the past 12 months.

CSL has a market capitalisation of around $128 billion based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 43% since December, ASX 300 healthcare share announces milestone achievement

The ASX healthcare stock is working across 140 clinical sites.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Two booming ASX healthcare stocks investors should be buying the dip on

Is this a buy the dip opportunity?

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why this beaten down ASX 200 healthcare stock could rebound 66%

Bell Potter sees potential for this healthcare stock to deliver big returns from current levels.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Ahead of its earnings results, Macquarie reckons this healthcare company is severely undervalued

A surprise on the upside is a definite possibility.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Healthcare Shares

3 reasons to buy CSL shares today

A leading investment expert forecasts a stronger year ahead for CSL shares. Let’s see why.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Healthcare Shares

ASX 200 healthcare stock sinks 9% on FDA update

Let's see what this stock has announced on Thursday.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

3 reasons to buy this heavyweight ASX healthcare share

This one is for investors seeking quality, global reach, and durable earnings.

Read more »

A corporate man crosses his arms to make an X, indicating no deal.
Healthcare Shares

1 reason I'm never selling CSL shares

It might be tempting to offload this one but I think that would be the wrong move.

Read more »